Evogene
EVGN
38 hedge funds and large institutions have $2.8M invested in Evogene in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 7 closing their positions.
0.87% less ownership
Funds ownership: 1.46% → 0.59% (-0.87%)
10% less funds holding
Funds holding: 42 → 38 (-4)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
72% less capital invested
Capital invested by funds: $10M → $2.8M (-$7.23M)
87% less call options, than puts
Call options by funds: $25K | Put options by funds: $187K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$211K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$91.5K |
| 3 |
Morgan Stanley
New York
|
+$50.4K |
| 4 |
VF
Virtu Financial
New York
|
+$49.3K |
| 5 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$46K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$6.02M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$115K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$94K |
| 4 |
Millennium Management
New York
|
-$67.6K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$52.4K |
EVGN Hedge Fund Activity: Q1 2022 in Review
38 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q1 2022, worth a combined $2.8M — down 72% from $10M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of EVGN and 3 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 10 added.
The largest buyer was Renaissance Technologies, adding an estimated $211K. The largest seller was ARK Investment Management, exiting entirely with an estimated $6.02M sold.
- 38 institutional investors held Evogene (EVGN) as of Q1 2022, down from 42 in Q4 2021.
- Funds reported $2.8M of Evogene stock for Q1 2022, down 72% quarter-over-quarter.
- 3 funds opened new Evogene positions in Q1 2022 and 7 closed out, a net change of -4 holders.
- The largest Evogene buyer in Q1 2022 was Renaissance Technologies, an estimated $211K added.
- The largest Evogene seller in Q1 2022 was ARK Investment Management, an estimated $6.02M sold.
Based on aggregated 13F filings for Q1 2022.